Crossover Comparison of MultiHance and Dotarem

Brain Disease Clinical Trial

— BENEFIT  

Official title:

Phase IV, Double Blind, Multi-Center, Randomized, Two-Arm Crossover Study to Compare 0.1 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem and 0.05 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem in Magnetic Resonance Imaging (MRI) of the Brain

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02070380
• Other study ID #: MH-148
• Status: Active, not recruiting
• Phase: Phase 4
• First received: February 20, 2014
• Last updated: February 26, 2015
• Start date: February 2014
• Est. completion date: July 2015

Study information

• Verified date: February 2015
• Source: Bracco Diagnostics, Inc
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review BoardCzech Republic: Ethics CommitteeGermany: Ethics Commission
• Study type: Interventional

Clinical Trial Summary

This study aims at a comparison between MultiHance at a dose of 0.1 mmol/kg and 0.05 mmol/kg and Dotarem at a dose of 0.1 mmol/kg in brain tumor patients to show superiority of MultiHance.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 176
• Est. completion date: July 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Are at least 18 years of age or older

• Are able to give written informed consent and are willing to comply with the protocol requirements

• Are scheduled to undergo MRI

• Are willing to undergo two MRI procedures within 14 days

• Have confirmed or are highly suspected to have brain tumor(s) (primary or secondary), as determined by:

• Clinical/neurological symptomatology;

• Diagnostic testing, such as CT or previous MRI examinations; or

• Have had recent brain surgery and are to be evaluated for recurrence

Exclusion Criteria:

• Are pregnant or lactating females. Exclude the possibility of pregnancy:

• By testing on site at the institution within 24 hours prior to the start of each investigational product administration; or

• By history (i.e., tubal ligation or hysterectomy); or

• Post menopausal with a minimum of 1 year without menses

• Have any known allergy to one or more of the ingredients in the investigational products, or have a history of hypersensitivity to any metals

• Have congestive heart failure (class IV according to the classification of the New York Heart Association)

• Have suffered a stroke within a year

• Have received or are scheduled to receive any other contrast medium in the 24 hours preceding through the 24 hours following Exam 1, and in the 24 hours preceding through the 24 hours following Exam 2

• Have received or are scheduled to receive an investigational compound and/or medical device within 30 days before admission into the present study, through the 24 hours post-administration of the second investigational product

• Have moderate-to-severe renal impairment, defined as Glomerular Filtration Rate (GFR)/estimated GFR < 45 mL/min

• Have been previously entered into this study

• Have received or are scheduled for one of the following:

• Surgical or chemotherapeutic treatment within three weeks prior to the first examination or between the two examinations

• Initiation of steroid therapy between the two examinations

• Radiosurgery between the two examinations

• Have any contraindications to MRI such as a pace-maker, magnetic material (i.e., surgical clips) or any other conditions that would preclude proximity to a strong magnetic field

• Are suffering from severe claustrophobia

• Have any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post-dose follow-up examinations

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Brain Disease
• Brain Diseases

Intervention

Drug:
• Gadobenate

• Gadoterate

Locations

Country	Name	City	State
United States	Samaritan Health Services	Corvallis	Oregon

Sponsors (1)

Lead Sponsor	Collaborator
Bracco Diagnostics, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Scores on global diagnostic preference	To show superiority of a 0.1 mmol/kg dose of MultiHance as compared to 0.1 mmol/kg dose of Dotarem, in terms of the by-subject global diagnostic preference between exams (i.e., based on pre-dose + post-dose image sets).	Up to 14 days	No